Text size: AAA
Step into summer in the best shape of your life with these reports from Harvard Medical School.
Learn How

Start your exercise and fitness program and reap the benefits of being more fit, stronger and healthier!

Warmer weather is on the way and it's not too late to get in shape for the summer. These 3 reports can help you enjoy outdoor activities in the best shape of your life:

References for “Medications for Alzheimer’s disease”

APR 2011

Next Article:

Did you know?

You can get instant online access to all of the articles from the April 2011 issue of Harvard Mental Health Letter for only $5.

Already a subscriber? Login for complete instant access.

If you want a button/link to remove the box (not sure if you do or not...), it would look like this: Cancel

Atri A, et al. “Long-Term Course and Effectiveness of Combination Therapy in Alzheimer’s Disease,” Alzheimer’s Disease & Associated Disorders (July/Sept. 2008): Vol. 22, No. 3, pp. 209–21. http://www.ncbi.nlm.nih.gov.ezp-prod1.hul.harvard.edu/pubmed/18580597

Ballard C, et al. “The Dementia Antipsychotic Withdrawal Trial (DART-AD): Long-Term Follow-Up of a Randomised Placebo-Controlled Trial,” Lancet Neurology (Feb. 2009): Vol. 8, No. 2, pp. 151–57. http://www.ncbi.nlm.nih.gov.ezp-prod1.hul.harvard.edu/pubmed/19138567

Birks J. “Cholinesterase Inhibitors for Alzheimer’s Disease,” Cochrane Database of Systematic Reviews (Jan. 25, 2006): Doc. No. CD005593. http://www.ncbi.nlm.nih.gov.ezp-prod1.hul.harvard.edu/pubmed/16437532

Narang P, et al. “Antipsychotic Drugs: Sudden Cardiac Death Among Elderly Patients,” Psychiatry (Oct. 2010): Vol. 7, No. 10, pp. 25–9. http://www.ncbi.nlm.nih.gov.ezp-prod1.hul.harvard.edu/pubmed?term=narang%20p%2C%20antipsychotic

Robinson DM, et al. “Memantine: A Review of Its Use in Alzheimer’s Disease,” Drugs (June 1, 2006): Vol. 66, No. 11, pp. 1515–34. http://www.ncbi.nlm.nih.gov.ezp-prod1.hul.harvard.edu/pubmed?term=robinson%20dm%20memantine

Schneider LS, et al. “Treatment with Cholinesterase Inhibitors and Memantine of Patients in the Alzheimer’s Disease Neuroimaging Initiative,” Archives of Neurology (Jan. 2011): Vol. 68, No. 1, pp. 58–66. http://www.ncbi.nlm.nih.gov.ezp-prod1.hul.harvard.edu/pubmed/21220675

Sultzer DL, et al. “Clinical Symptom Responses to Atypical Antipsychotic Medications in Alzheimer’s Disease: Phase 1 Outcomes from the CATIE-AD Effectiveness Trial,” American Journal of Psychiatry (July 2008): Vol. 165, No. 7, pp. 844–54. http://www.ncbi.nlm.nih.gov.ezp-prod1.hul.harvard.edu/pubmed/18519523

Next Article: